Amongst all existing treatment modalities, semaglutide injection is the proven most effective glucagon-like peptide-1 (GLP-1) receptor agonist for obesity, but high costs limit global accessibility. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.